A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With Beta-Thalassemia Treated With Base-edited Autologous Hematopoietic Stem Cell (CS-101) Transplantation

What this Trial Is About

This research aims to evaluate the long-term safety and effectiveness of CS-101 in participants who previously received CS-101 in an earlier study (CS-101-03). It focuses on individuals with beta-thalassemia who underwent treatment with this base-edited autologous hematopoietic stem cell transplantation. The study is led by the Children's Hospital of Fudan University and monitors participants up to two years after their infusion. Participants in this follow-up study have completed the initial CS-101-03 trial where they received the CS-101 infusion. This current study tracks their health and treatment outcomes for up to two years after the last six-month follow-up visit post-infusion. The study does not introduce new treatments but observes the long-term effects of the prior CS-101 therapy. During the study, participants will undergo evaluations for serious adverse events, death, new cancers or blood disorders, and whether they achieve transfusion independence for at least 12 consecutive months. Researchers will also monitor changes in fetal and total hemoglobin levels, and the genetic modification presence in blood and bone marrow cells. All assessments occur from the time of consent through two years post-infusion, with safety and efficacy carefully observed throughout this period.

A Long-term Follow-up Study in Participants Who Received CS-101